does medicaid pay for glp 1 drugs Navigating Changes to GLP-1 Medication Coverage California Medi-Cal halts GLP-1 obesity

Part 1 of 2 covers the mechanism and the U/kg trend, the portal-peripheral mismatch, and the Ominous Octet framework

Local Manufacturing And Fill-Finish Investments Lower Supply Risk Novo Nordisks USD 1.09 billion upgrade to its Montes Claros complex, announced in April 2025, will begin producing GLP-1 pens domestically in late 2026, shielding the Latin America GLP-1 agonists market from future import bottlenecks

Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment

The market growth is driven by drugs with increasing potency to induce weight loss, more convenient oral formulations that help drive adoption as well as increasing interest from non-obese patients looking for weight loss alternatives to diet & exercise